Financial Distress in Genitourinary Cancer: Insights From CDC National Health Interview Survey
JCO Oncology Practice · 2024
DOI: 10.1200/op.23.00733 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2024. Verfasst von Steven Leonard und 14 weiteren Autor:innen. Beteiligte Einrichtung: Fox Chase Cancer Center, Philadelphia, PA. Hauptthemen laut MEDLINE: Financial Stress, Urogenital Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE This study leverages CDC National Health Interview Survey data to examine Financial Distress (FD) among genitourinary (GU) cancer survivors, specifically prostate cancer (PC), kidney cancer (KC), and bladder cancer (BC). It investigates the economic impacts faced by these patients, especially in relation to disparities in insurance coverage and its effects on material, psychological, and behavioral aspects of FD. METHODS We retrospectively analyzed responses from GU cancer survivors, stratifying by cancer status and age (18-64 years, ≥65 years). Medical financial hardship was divided into three domains: material, psychological, and behavioral. Associations between cancer history, hardship, and clinical factors were assessed using generalized ordinal logistic regressions. RESULTS Significant health care access disparities were found, particularly for mental health services, with 25% of younger BC survivors and 4.7% of younger KC survivors reporting affordability issues, in contrast to 2.7% of noncancer individuals. Dental care was also problematic, with higher avoidance rates among younger BC (27%) and KC (15%) survivors compared with the general population. Surprisingly, noncancer individuals reported more difficulty in affording prescriptions than BC survivors across both age groups. PC survivors, however, showed lower FD across all domains versus noncancer controls, indicating fewer concerns about medical bills and a lesser tendency to forgo care. CONCLUSION The study underscores significant gaps in the financial support system for GU cancer survivors, with urgent needs in mental and dental health care access. Policy interventions, including comprehensive insurance reforms, are imperative to alleviate the financial burdens on these individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Fox Chase Cancer Center, Philadelphia, PA.
- India Institute of Technology, Delhi, India.
- Case Western Reserve School of Medicine, Cleveland, OH.
- University Hospitals Cleveland Medical Center, Cleveland, OH.
- University of Washington Medical Center, Fred Hutchinson Cancer Center, Seattle, WA.
- Division of Urology, Department of Surgery, Medical College of Georgia, Augusta University, Augusta, GA.
ORCID-Profile: Andres Correa, Mohit Sindhani, Angela Y Jia, Sarah P Psutka, Zachary Klaassen, Michael Staehler, Christopher J D Wallis, Laura Bukavina
Zitieren
APA
Leonard, S., Helstrom, E., Correa, A., Sindhani, M., Uzzo, N., Jia, A. Y., Kutikov, A., Uzzo, R., Psutka, S. P., Calaway, A., Klaassen, Z., Staehler, M., Smaldone, M., Wallis, C. J. D., & Bukavina, L. (2024). Financial Distress in Genitourinary Cancer: Insights From CDC National Health Interview Survey. JCO Oncology Practice. https://doi.org/10.1200/op.23.00733
Vancouver
Leonard S, Helstrom E, Correa A, Sindhani M, Uzzo N, Jia AY, et al. Financial Distress in Genitourinary Cancer: Insights From CDC National Health Interview Survey. JCO Oncology Practice. 2024. doi:10.1200/op.23.00733
BibTeX
@article{Leonard2024,
author = {Leonard, Steven and Helstrom, Emma and Correa, Andres and Sindhani, Mohit and Uzzo, Nicole and Jia, Angela Y and Kutikov, Alexander and Uzzo, Robert and Psutka, Sarah P and Calaway, Adam and Klaassen, Zachary and Staehler, Michael and Smaldone, Marc and Wallis, Christopher J D and Bukavina, Laura},
title = {Financial Distress in Genitourinary Cancer: Insights From CDC National Health Interview Survey},
journal = {JCO Oncology Practice},
year = {2024},
doi = {10.1200/op.23.00733}
}
EUVIMED